 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and Treatment Resistant 
Minimal Change Disease  
 
Principal Investigator s: Zubin Modi, MD, MS  & Howard Trachtman, MD  
Sponsored by: University of Michigan  
Protocol Version Number:  v. 5.0 
 
IND Number: 143167  
Study ID: [REMOVED]  
 
Protocol Date: 2/15/2019  
Amendment 1: 4/1/2020  
Amendment 2: 12/1/2020  
Amendment 3: 07/28/2021  
Amendment 4: 02/21/2023  
 
  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023   
 
3 
 Table of Contents  
LIST OF ABBREVIATIONS  ................................ ................................ ................................ ................................ .......  1 
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ .............................  1 
PROTOCOL SUMMARY  ................................ ................................ ................................ ................................ ...........  2 
SCHEMATIC OF STUDY DESIGN  ................................ ................................ ................................ ..........................  3 
1 KEY ROLES  ................................ ................................ ................................ ................................ ....................  5 
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ........................  6 
2.1 Background Information  ................................ ................................ ................................ ......................  6 
2.2 Rationale  ................................ ................................ ................................ ................................ ...............  6 
2.3 Potential Risks and Benefits  ................................ ................................ ................................ ..............  9 
2.3.1 Known Potential Risks  ................................ ................................ ................................ ..... 9 
2.3.2  Potential Benefits  ................................ ................................ ................................ ...........  11 
3 OBJECTIVES AND PURPOSE  ................................ ................................ ................................ ..................  11 
4 STUDY DESIGN AND ENDPOINTS  ................................ ................................ ................................ .........  11 
4.1 Description of the Study Design  ................................ ................................ ................................ ...... 11 
4.2 ENDPOINTS  ................................ ................................ ................................ ................................ .......  11 
4.2.1  Primary Endpoi nt ................................ ................................ ................................ ............  11 
4.2.2  Secondary Endpoints  ................................ ................................ ................................ .... 11 
4.2.3  Exploratory Endpoints  ................................ ................................ ................................ ... 11 
5 STUD Y ENROLLMENT AND WITHDRAWAL  ................................ ................................ .........................  12 
5.1 Participant Inclusion Criteria  ................................ ................................ ................................ ............  12 
5.2 Participant Exclusion Criteria  ................................ ................................ ................................ ...........  12 
5.3 Strategies for Recruitment and Retention  ................................ ................................ ......................  13 
5.4 Participant Withdrawal or termination  ................................ ................................ .............................  13 
5.5 Premature Termination or Suspension of Study  ................................ ................................ ...........  13 
6 STUDY AGENT  ................................ ................................ ................................ ................................ ............  14 
6.1 Study Agent(s) and Control Description  ................................ ................................ .........................  14 
6.1.1  Acquisition  ................................ ................................ ................................ .......................  14 
6.1.2  Formulation, Appearance, Packaging, and Labeling  ................................ ................  14 
6.1.3  Product Storage and Stability  ................................ ................................ .......................  14 
6.1.4  Dosing  15 
6.1.5  Route of Administration  ................................ ................................ ................................ . 15 
6.1.6  Dose Adjustments/Modifications/Delays  ................................ ................................ .... 15 
6.1.7  Duration of Therapy  ................................ ................................ ................................ .......  15 
6.2 Study agent Accountability Procedures  ................................ ................................ ..........................  15 
6.2.1  Responsibilities of the Clinical Site Pharmacy  ................................ ...........................  15 
6.2.2  The Site Investigator Responsibility  ................................ ................................ ............  15 
7 STUDY PROCEDURES AND SCHEDULE  ................................ ................................ ..............................  15 
7.1 Study Procedures/Evaluations  ................................ ................................ ................................ .........  15 
7.2 Study Schedule  ................................ ................................ ................................ ................................ .. 17 
7.2.1  Screenin g Visit  ................................ ................................ ................................ ................  17 
7.2.2  Baseline/Week 0  ................................ ................................ ................................ ............  18 
7.2.3  Follow -up ................................ ................................ ................................ .........................  18 
7.2.4  Early Termin ation Visit  ................................ ................................ ................................ .. 19 
7.2.5  Schedule of Events Table  ................................ ................................ .............................  19 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023   
 
4 
 7.3 Justification for Sensitive Procedures  ................................ ................................ .............................  20 
7.4 Concomitant Medications, Treatments, and Procedures  ................................ .............................  20 
7.5 Prohibited Medications, Treatments, and Procedures  ................................ ................................ . 20 
7.6 Participant Access to Study Agent At Study Closure  ................................ ................................ ... 20 
8 ASSESSMENT OF SAFETY  ................................ ................................ ................................ ......................  20 
8.1 Specif ication of Safety Parameters  ................................ ................................ ................................ . 21 
8.1.1  Definition of Adverse Events (AE)  ................................ ................................ ...............  21 
8.1.2  Definition of Serious Adverse Events (SAE)  ................................ ..............................  21 
8.1.3  Pregnancy  ................................ ................................ ................................ .......................  22 
8.2 Classification of an Adverse Event  ................................ ................................ ................................ . 22 
8.2.1  Severity of Event  ................................ ................................ ................................ ............  22 
8.2.2  Relationship to Study Agent  ................................ ................................ .........................  23 
8.2.3  Expectedness  ................................ ................................ ................................ .................  23 
8.3 Time Period and Frequency for Event Assessment and Follow -Up ................................ ..........  23 
8.4 Reporting Procedures  ................................ ................................ ................................ .......................  23 
8.4.1  Adverse Event Reporting  ................................ ................................ ..............................  23 
8.4.2 Serious Adverse Event Reporting  ................................ ................................ ...............  23 
8.5 Study Halting Rules  ................................ ................................ ................................ ...........................  24 
8.6 Safety Oversight  ................................ ................................ ................................ ................................  24 
9 CLINICAL M ONITORING  ................................ ................................ ................................ ............................  24 
10 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ..........  25 
10.1  Statistical and Analytical Plans  ................................ ................................ ................................ ........  25 
10.2  Analysis Datasets  ................................ ................................ ................................ ..............................  25 
10.3  Description of Statistical Methods  ................................ ................................ ................................ ... 25 
10.3.1  General Approach  ................................ ................................ ................................ ..........  25 
10.3.2  Analysis of the Primary Efficacy Endpoint(s)  ................................ .............................  25 
10.3.3  Analysis of the Secondary Endpoint(s)  ................................ ................................ .......  25 
10.3.4  Safety Analyses  ................................ ................................ ................................ ..............  25 
10.3.5  Adherence and Retention Analyses  ................................ ................................ ............  26 
10.3.6  Baseline Descriptive Statistics  ................................ ................................ .....................  26 
10.3.7  Tabulation of Individual Response Data  ................................ ................................ ..... 26 
10.3.8  Exploratory Analyses  ................................ ................................ ................................ ..... 26 
10.4  Sample Size  ................................ ................................ ................................ ................................ .......  26 
11 SOURCE DOCUME NTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................ ... 26 
12 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................ ................................ ...................  27 
12.1  Ethical Standard  ................................ ................................ ................................ ................................ . 27 
12.2  Institutional Review Board  ................................ ................................ ................................ ................  27 
12.3 Informed Consent Process  ................................ ................................ ................................ ...............  27 
12.4  Participant and data Confidentiality  ................................ ................................ ................................  27 
12.5  Future Use of Stored Specimens  ................................ ................................ ................................ .... 28 
13 DATA HANDLING AND RECORD KEEPING  ................................ ................................ ..........................  28 
13.1  Data Collection and Management Responsibilities  ................................ ................................ ...... 28 
13.2  Study Records Retention  ................................ ................................ ................................ ..................  28 
13.3  Protocol Deviations ................................ ................................ ................................ ............................  28 
13.4  Publication and Data Sharing Policy  ................................ ................................ ...............................  28 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023   
 
5 
 14 CONFLICT OF INTEREST POLICY  ................................ ................................ ................................ ..........  28 
15  LITERATURE REFERENCES ................................ ................................ ................................ ....................  28 
APPENDIX  ................................ ................................ ................................ ................................ ................................ . 29 
 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   1 LIST OF ABBREVIATION S 
 
DSMB  Data Safety and Monitoring Board  
EGF Epidermal Growth Factor  
ESKD  End Stage Kidney Disease  
FSGS  Focal Segmental Glomerulosclerosis  
MCP1  Monocyte Chemoattractant Protein 1  
TIMP1  Tissue Inhibitor of Metalloproteinase 1  
MCD  Minimal Change Disease  
TNF Tumor Necrosis Factor  
UPC Urine Protein:Creatinine Ratio  
 
STATEMENT OF COMPLIA NCE  
This trial will be conducted with Good Clinical Practice (GCP) and in accordance with the Code of Federal 
Regulations on the Protection of Human Subjects (21 CFR Part 50). The Principal Investigator will assure 
that no deviation from, or changes to the pro tocol will take place without documented approval from 
the applicable Institutional Review Boards (IRBs), except where necessary to eliminate an immediate 
hazard(s) to the trial participants. All personnel involved in the conduct of this study have complet ed 
Human Subjects Protection Training.  
  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   2  
PROTOCOL SUMMARY  
Title:  Precision Medicine Proof of Concept for TNF inhibition in FSGS and 
Treatment Resistant Minimal Change Disease  
Précis:  A Proof of Concept, multi -center, open label, clinical trial addressin g the 
treatment of patients with focal segmental glomerulosclerosis (FSGS) or 
treatment resistant minimal change disease (TR -MCD). Up to 8 patients 
with intra -renal tumor necrosis factor (TNF) up -regulation will be treated 
with 8 weeks of adalimumab therap y. The primary assessment will be of 
the change in target engagement biomarker levels of urinary TIMP1/Cr or 
MCP1/Cr from baseline to study week 10. Key secondary outcomes 
include safety measures, serious adverse events, and adverse events.  
 
Objectives:  
 This study is proposed to test the hypothesis that FSGS and TR -MCD 
patients with up -regulation of the TNF pathway can be identified through 
intra -renal gene expression profiling and assay of urine MCP1/Cr and 
TIMP1/Cr levels by ELISA.  
 
Furthermore, this study will test the hypothesis that TNF inhibition with 
adalimumab (Humira) in patients with up -regulation of the intra -renal TNF 
pathway will result in reduction in urinary MCP1/Cr and/or TIMP1/Cr 
biomarker levels.  
Endpoint  Primary Endpoint: The change in urine MCP1/Cr and TIMP1/Cr levels from 
baseline to study week 10, i.e. 2 weeks after the final dose of adalimumab  
 
Secondary Endpoints  
(1) Incidence of serious adverse events, adverse events and abnormal 
laboratory tests  
(2) Perce nt change of eGFR from baseline to week 10  
(3) Percent change in urine protein:creatinine (UPC) from baseline to 
week 10  
(4) Proportion of participants achieving a nadir UPC less than 1.5 g/g 
and at least a 40% reduction from baseline at week 10.   
 
Exploratory Endpoints  
(1) Correlation coefficient between intra -renal gene expression of TNF 
and urinary MCP1/Cr and TIMP1/Cr biomarker levels at baseline  
(2) Time to reduction of urinary MCP1/Cr and TIMP1/Cr biomarkers 
from baseline  
(3) Change in urinary EGF biomarker levels bet ween baseline and 
week 10  
(4) Change in Quality of Life score between baseline and week 10.  
 
Population:  
 
 
 Up to eight patients with kidney biopsy confirmed FSGS or TR - MCD, 
increased urinary excretion of biomarkers of TNF activation (MCP1/Cr and 
TIMP1/Cr) at study screening, eGFR> 30 ml/min/1.73 m2 at enrollment, 
urine protein:creatinine (UPC) ratio ≥1.5 g/g at enrollment, age between 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   3 6-80 years, inclusive, and stable therapy with angiotensin converting 
enzyme inhibitors, angiotensin receptor blockers, and o ral 
immunosuppression agents for at least 30 days prior to enrollment will be 
enrolled and entered into the intervention phase of the study. Additional 
eligibility criteria are listed in the inclusion and exclusion criteria section 
below.  
Phase:  Proof of  Concept/Phase 1b/2a  
 
Number of Sites 
enrolling participants:  Up to 8 sites in the USA will participate in this study.  
 
Description of Study 
Agent :  Humira, adalimumab  
Manufactured by Abbvie  
Subcutaneous  
A total of 5 doses will be administered during the  trial at weeks 0, 2, 4, 6 
and 8. Dosing will be based on weight:  
Subject Weight  Adalimumab dose every other week  
15kg to <30kg  20mg  
>30kg  40mg  
 
Study Duration:  Approximately 14 months  
1. 7 month enrollment phase  
2. 2 week screening, 8 week intervention and  6 week post 
intervention observation period for a total of 14 week 
participation per patient  
3. 3 month analysis phase  
 
Participant Duration:  16 weeks  
1. 2 week screening period  
2. 8 week intervention period  
3. 6 week follow up post treatment  
 
SCHEMATIC OF STUDY DESIGN  
 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   4   

Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   5  
1 KEY ROLES  
Administrative Coordinating Center  
University of Michigan  
1500 E. Medical Center Drive  
Ann Arbor, MI 48109    
  Study Principal Investigator  
Zubin Modi, MD, MS  
Assistant Professor of Pediatrics  
University of Michigan  
1500 E. Medical Center Drive  
Ann Arbor, MI 48109  
Phone 734 -232-4830  
Fax 734 -232-2353  
Email: modiz@med.umich.edu  
Co-Principal Investigator and Medical Monitor  
Howard Trachtman, MD  
University of Michigan  
Co-Investigator  and Medical Monitor  
Karthik Ramani, MD,  
University of Michigan  
 Director, Biomarker Core  
Wenjen Ju, PhD  
University of Michigan  
 Director, Gene Expression and Bioinformatics Core  
Matthias Kretzler, MD  
University of Michigan  
Data Coordinating Center  
University of Michigan  
Ann Arbor, MI 48109 -2029   Principal Statistician & Director of Data Coordinating Center  
Cathie Spino, D.Sc.  
Research Professor of Biostatistics  
Director, Statistical Analysis of Biomedical  
and Educational Research (SABER) Unit  
School of Public Health  
University of Michigan  
1415 Washington Heights, Rm M4507  
Ann Arbor, MI 48109 -2029  
Tel: (734) 615 -5469  
Fax: (734) 647 -3711  
Email: spino@med.umich.edu  
 
  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   6  
2  INTRODUCTION: BAC KGROUND INFORMATION AND SCIE NTIFIC RATIONALE  
 
2.1 BACKGROUND INFOR MATION  
FSGS is a pattern of kidney injury that manifests as isolated, asymptomatic proteinuria or nephrotic 
syndrome. It is a serious condition and may lead to kidney failure in up to 50% of patie nts over a five to 
ten year period. Although primary FSGS is a rare entity, the incidence of the disease has been steadily 
rising over the last 30 years and it is generally the most common form of primary glomerular disease in 
all patient subgroups. Moreov er, it one of the leading causes of chronic and end -stage kidney disease 
(ESKD), accounting for 5% of adult and 12% of pediatric ESRD cases.  
 
The first -line therapy for primary FSGS, especially in those with nephrotic -range proteinuria, is usually 
corticos teroids. In patients who are unresponsive to steroids, calcineurin inhibitors (CNIs) are the 
recommended second -line therapy according to current KDIGO clinical guidelines1. Overall, 
approximately 20% of patients wit h FSGS will have a favorable response to corticosteroids and up to 
40% will have clinical benefit from treatment with a calcineurin inhibitor. Other agents that have been 
tried with marginal success include mycophenolate mofetil and rituximab. Patients wit h treatment -
resistant FSGS are at higher risk of progressing to ESKD.  
 
Adjuvant therapies designed to reduce proteinuria in primary FSGS are mainly focused on agents that 
inhibit renin -angiotensin system including angiotensin -converting enzyme inhibitors (ACEIs), angiotensin 
II receptor blockers (ARBs), or aldosterone antagonists. This is based on evidence that reduction in 
proteinuria in response to treatment is renoprotective and an independent predictor of kidney survival.  
These clinical data underscore  the limitations of current therapy for FSGS and highlight the need to 
develop new strategies to safely and effectively achieve a reduction in proteinuria, either a partial or 
complete remission, preservation of kidney function and minimization of the adve rse effects due to 
reduction of exposure to agents with little expectation of efficacy.  
 
While there are many insults that result in FSGS, molecular profiling can result in identifiable subgroups 
of affected patients with discrete pathophysiological mechanisms that may inform a precision medicine 
driven next generation of treatment strategies for individuals with FSGS and treatment resistant MCD.  
 
2.2 RATIONALE  
Based on molecular profiling, informed therapy selection targeting the underlying disturbance has been 
used successfully in health care and biomedical research. When successful, this f orms the basis of 
precision medicine for the treatment of selected patient populations.     
 
The Nephrotic Syndrome Study Network (NEPTUNE, PI M. Kretzler) study investigators have used 
genome wide expression profiles of renal biopsy specimens available fr om more than 250 patients to 
identify molecular subgroups of NS2. Three distinct patient subgroups were identified and associated 
with long -term outcomes. Molecular pathway analysis of the subgroups with TR -MCD and FSGS showed 
activation of TNF as defined by causal inference network analysis of established downstream pathway 
members, including TIMP1 and MCP1 in one of the 3 subgroups. These patients presented with higher 
levels of proteinuria, lower levels of GFR, an d more rapid progression of their glomerular disease. A TNF 
Z-score was computed for each NEPTUNE participant with MCD and FSGS.  The score is the average Z -
score of gene expression level across 145 TNF pathway genes from the tubulointerstitial compartment  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   7 of each participant’s renal biopsy.  Urinary MCP1 and TIMP1 were measured by ELISA from their 
baseline study visit and normalized to urine creatinine.  Correlations of TNF gene expression Z -score 
with urinary biomarkers are shown in Figure 1 and distribut ions of these measures in boxplots from TNF 
z-score < 0 vs > 0 are plotted in Figure 2.  
 
Figure 2:   Scatter plot of TNF z - score and urinary TIMP1/Cr, A: All FSGS and MCD patients (corr = 
0.47, P<0.001) TNF z -score and urinary MCP1/Cr, B: All FSGS and MCD patients (corr = 0.51, 
P<0.001) TNF z -score and urinary TIMP1/Cr ng/mg. (L. Mariani, et al 2017)  
A.                                                                            B.  
  
 
Figure 3:  Distribution of biomarker level by TNF Z -score category.  Difference in means was 
statistically significant (TIMP1, p -value 0.009; MCP1 p -value 0.001) (L. Mariani, et al 2017)  
 
 
A logistic model was fit with the outcome of TNF Z -score >0 to assess the predictive ability of urinary 
biomarkers individually and combined.  Results are shown in Table 1 for the subgroup of participants 
with eGFR >45.  Model 3, which included both biomar kers as predictors had the highest positive 
predictive value and correct classification.  Correctly classified was calculated by assigning those with an 
estimated probability of disease >= 50% as having disease and then calculating the % that are correctly  
classified as having and not having disease (true TNF Z -score > vs <= 0) using a patient sample with eGFR 
> 45 and either FSGS or MCD.  
 

Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   8 Table 1:  Results of Multivariable Logistic Models of TNF Z -score >0 in NEPTUNE FSGS and MCD 
participants with eGFR>45  
Patients with eGFR >45  
(n = 49; 13 Events)  Model 1  
c-statistic 0.79  
PPV 33%  
correctly classified 69%  Model 2  
c-statistic 0.79  
PPV 67%  
Correctly classified 78%  Model 3  
c-statistic 0.82  
PPV 75%  
Correctly Classified 82%  
 OR P-value  OR P-value  OR P-value  
Log2(uTIMP/Cr)  1.79  0.017  -- -- 1.54  0.07  
Log2(uMCP/Cr)  -- -- 2.31  0.008  1.81  0.08  
 
Because both biomarkers contributed to greater predictive accuracy, both will be measured for patient 
selection into the clinical trial.  The coefficients from the multivariable model will be used to calculate 
the odds of having a TNF Z -score >0 for each p erson.  Odds are then converted to probability and 
patients with a probability >= 50% of having a positive TNF Z -score would be eligible for enrollment.   
Mathematically, the following equations will be used to calculate the probabilities for study inclusi on: 
1. Constant + [log2(uTIMP1/Cr) * Coef1] + [log2(uMCP1/Cr) * Coef2] = log Odds  
2. Exp(log Odds) = Odds  
3. Probability = Odds / (1 + Odds)  
 
Using the following coefficients and constant from Model 3 in Table 2:  
 
i.e., log Odds = -1.001269 + 0.59214 * log2(uTIMP1/Cr) +0.4325066 * log2(uMCP1/Cr).  
 
In NEPTUNE, these molecular pathway -defined patient subgroups characterized by high intra -renal TNF 
activation have documented persistence in proteinuria and reduced kidney function during prospective 
observati on. Past studies of TNF inhibition in unselected treatment resistant FSGS patients 
demonstrated a reduction in proteinuria and preservation of estimated glomerular filtration rate (eGFR) 
in approximately 25% of studied patients3. In the FONT study, there were no clinical or laboratory 
findings that predicted response patterns to TNF -inhibition.  This study also identified the accelerated 
clearance of the TNF monoclonal antibody in this patient population with signifi cant proteinuria 4-6. On 
average the Area Under the Curve (AUC) was 50% lower than that of comparison populations without 
proteinuria. In a parallel study of a small therapeutic compound, similar reduction in AUC in  proteinuric 
patients with FSGS was documented suggesting that both large and small molecules are cleared more 
rapidly in patients with proteinuric kidney diseases such as FSGS and TR -MCD7. The recent findings 
withi n the NEPTUNE investigative community suggest that we may now have a mechanism to identify 
TNF-target relevant patients with primary nephrotic syndrome and use prior evidence to select a likely 
drug dosing regimen for this patient population.  
 

Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   9 2.3 POTENTI AL RISKS AND BENEFIT S  
 
2.3.1  KNOWN POTENTIA L RISKS  
SERIOUS INFECTIONS  
Some patients treated with Humira (adalimumab) are at increased risk for developing serious infections 
that may lead to hospitalization or death.  Most patients who developed these infections were taking 
concomitant immunosuppressants such as methotrexate or corticosteroids.  
 
Reported infections include:  
Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented 
with disseminated or extrapulmonary disease. Study participants will be tested for TB before starti ng 
Humira.  
 
Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, 
blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may 
present with disseminated, rather tha n localized, disease. Antigen and antibody testing for 
histoplasmosis may be negative in some patients with active infection. Consider empiric anti -fungal 
therapy in patients at risk for invasive fungal infections who develop severe systemic illness.  
Bacte rial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.  
 
MALIGNANCIES  
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients 
treated with TNF blockers, including Humi ra. Postmarketing cases of hepatosplenic T -cell lymphoma 
(HSTCL), a rare type of T -cell lymphoma, have been reported in patients treated with TNF blockers, 
including Humira. These cases have had a very aggressive disease course and have been fatal. The 
majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative 
colitis and the majority were in adolescent and young adult males. Almost all of these patients had 
received treatment with azathioprine or 6 -mercaptopurine co ncomitantly with a TNF blocker at or prior 
to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF 
blocker in combination with these other immunosuppressants.  
 
HYPERSENSITIVITY  
Anaphylaxis and angioneurotic  edema have been reported following Humira administration. If a serious 
allergic reaction occurs, stop Humira and institute appropriate therapy.  
 
HEPATITIS B VIRUS REACTIVATION  
Use of TNF blockers, including Humira, may increase the risk of reactivation of  hepatitis B virus (HBV) in 
patients who are chronic carriers. Some cases have been fatal. Study participants will be screened for 
HBV. Those with prior evidence of HBV infection will not be allowed to participate in this study.   
 
NEUROLOGIC REACTIONS  
TNF blockers, including Humira, have been associated with rare cases of new onset or exacerbation of 
central nervous system and peripheral demyelinating diseases, including multiple sclerosis, optic 
neuritis, and Guillain -Barré syndrome. Participants with the se disorders will be excluded from the study. 
If any of these disorders develop, Humira will be discontinued.  
 
HEMATOLOGIC REACTIONS  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   10 Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. 
Medically significant cytop enia has been infrequently reported with Humira.  
 
CONGESTIVE HEART FAILURE  
Worsening and new onset congestive heart failure (CHF) has been reported with TNF blockers. Cases of 
worsening CHF have been observed with Humira. Participants with known CHF will be excluded from the 
study.  
 
AUTOIMMUNITY  
Treatment with Humira may result in the formation of autoantibodies and, rarely, in development of a 
lupus -like syndrome. Discontinue treatment if symptoms of a lupus -like syndrome develop.  
 
IMMUNIZATIONS  
Patients on Humira should not receive live vaccines. Pediatric patients, if possible, should be brought up 
to date with all immunizations before initiating Humira therapy. Adalimumab is actively transferred 
across the placenta during the third trimester of pregnanc y and may affect immune response in the in 
utero exposed infant. The safety of administering live or live -attenuated vaccines in infants exposed to 
Humira in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live -
atten uated) exposed infants.  
 
ADVERSE REACTIONS  
The most common adverse reactions in Humira clinical trials (>10%) were: infections (e.g., upper 
respiratory, sinusitis), injection site reactions, headache, and rash.  
 
Directly relevant to this protocol , two smal l studies of TNF -inhibition with monoclonal antibody therapy 
in children and adults with multi -drug resistant FSGS have been reported.  
 
Table 3. FONT trial summary of reported adverse events in 17 treated patients  
Event  Frequency (% of patients reporting)  
Severe Adverse Events   
   Infection with hospitalization  30% (5/17)  
   Malignancy  0 
   Death  0 
Other Adverse Events   
   GI 24% (4/17)  
 
Approaches to reduce risks associated with study drugs  
Due to the frequent and sometimes serious risks associated with the study drug, specific measures have 
been instituted to minimize these risks and improve the risk:benefit ratio for participants. Based on past 
experience with the administration of immunosu ppressive therapies to patients with FSGS and TR -MCD, 
the inclusion and exclusion criteria have been selected to enrich for subjects most -likely to benefit from 
therapy (see Inclusion Criteria) and to avoid those subjects who are less -likely to benefit or more likely 
to experience treatment -related toxicity (see Exclusion Criteria).  Pregnancy status will be monitored 
throughout the study. In addition, frequent and routine laboratory monitoring will be carried out 
throughout the study protocol. The Clinical  Investigator is responsible for reviewing and acting on 
adverse events in accordance with section 6.1.7.  
 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   11 2.3.2  POTENTIAL BENE FITS  
In previous studies 4 of 17 (24%) of unselected patients with multi -drug resistant FSGS experienced a 
50% reduction in pro teinuria and preservation of eGFR with the use of TNF -inhibitor with monoclonal 
antibody therapy over a 16 week period5.  
 
3 OBJECTIVES AND PUR POSE  
 
The primary purpose of this Proof of Concept study is to test the hypothesis that TNF inhibition with 
adalimumab (Humira) in patients with up -regulation of the intra -renal TNF pathway will result in 
reduction in urinary indicators of TNF pathway activation, specifically urine MCP1/Cr and TIMP1/Cr 
levels.   
 
Furthermore, this study is proposed to test the hypothesis that FSGS patients with up -regulation of the 
TNF pathway can be identified through intra -renal gene expression profiling and assay of urine MCP1/Cr 
and TIMP1/Cr levels by ELISA.  
 
4 STUDY DESIGN AND E NDPOINTS  
 
4.1 DESCRIPTION OF T HE STUDY DESIGN  
 
This Proof of Concept, multi -center, open label, clinical trial addresses the treatment of patients with 
clinically active FSGS or TR -MCD. Up to eight patients with urinary MCP1/Cr and TIMP1/Cr urinary 
biomarker levels indicating intra -renal tumor necrosis factor (TNF) upregulation will be treated with 8 
weeks of adalimumab therapy to assure a minimum evaluable study sample of six patients. The Humira 
will be dosed based on weight and administered subcutaneously  every tw o weeks for 8 weeks (5 total 
doses). The urinary biomarkers MCP1/Cr and TIMP1/Cr will be assessed throughout the study.  The 
primary assessment will be of the reduction in target engagement biomarker levels of urinary TIMP1/Cr 
or MCP1/Cr from baseline to s tudy week 10. Key secondary outcomes include safety measures, serious 
adverse events, and adverse events.  
 
4.2 ENDPOINTS  
 
4.2.1  PRIMARY ENDPOI NT 
The change in urine MCP1/Cr and TIMP1/Cr levels from baseline to study week 10, i.e. 2 weeks after the 
final dose of adalimumab.  
 
4.2.2  SECONDARY ENDP OINTS  
(1) Incidence of serious adverse events, adverse events and abnormal laboratory tests  
(2) Percent change of eGFR from baseline to week 10  
(3) Percent change in UPC from baseline to week 10  
(4) Proportion of participants achi eving a nadir UPC less than 1.5 g/g and at least a 40% reduction 
from baseline at week 10.  
 
4.2.3  EXPLORATORY EN DPOINTS  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   12 (1) Correlation coefficient between intra -renal gene expression of TNF and urinary MCP1/Cr and 
TIMP1/Cr biomarker levels at baseline  
(2) Time to  reduction of urinary MCP1/Cr and TIMP1/Cr biomarkers from baseline  
(3) Change in urinary EGF biomarker levels between baseline and week 10  
(4) Change in Quality of Life score between baseline and week 10.  
 
Endpoint Rationale:  
The target engagement biomarkers, ur ine MCP1/Cr and TIMP1/Cr, will be the primary endpoints of 
this study as we hypothesize that the levels of this biomarkers at baseline reflect TNF up -regulation 
in the kidney and after TNF inhibition will reflect target engagement. Neither eGFR nor urinary  
protein will be a primary endpoint measure. However, we will measure eGFR and urinary protein to 
provide estimates for future trials  
 
5 STUDY ENROLLMENT A ND WITHDRAWAL  
 
5.1 PARTICIPANT INCL USION CRITERIA  
1. Kidney biopsy confirmed FSGS or MCD  
2. For Minimal Change Disease patients only, history of resistance to corticosteroid therapy  
3. Increased urinary excretion of biomarkers of TNF activation (MCP1/Cr and/ or TIMP1/Cr) at 
study screening  
4. eGFR> 30 ml/min/1.73 m2 at screening  
5. Urine protein:creatinine ratio ≥1.5 g/g at screening  
6. Age 6 -80 years  
7. Weight >15kg  
8. Stable therapy with angiotensin converting enzyme inhibitors, angiotensin receptor blockers, 
and oral immunosuppression agents for at least 30 days prior to enrollment  
9. Birth control use in females of child bear ing potential  
10. Informed consent and assent if applicable  
 
5.2 PARTICIPANT EXCLUSIO N CRITERIA  
1. Kidney or other solid organ or bone marrow transplant recipient  
2. Allergy or intolerance to investigational agent  
3. Secondary FSGS  
4. Severe obesity, i.e., BMI >40 kg/m2  
5. Live virus vaccine in the past 3 months  
6. Malignancy, current or in the past 5 years  
7. Active local or systemic bacterial, fungal or viral infection  
8. Active or latent Hepatitis B, Hepatitis C, HIV, or tuberculosis defined as quantiferon test positive   
9. History of demyelinating disease, e.g. Multiple Sclerosis or Guillain -Barre  
10. History of heart failure  
11. Active liver disease, defined as AST or ALT > 2.5x Upper Limit of Normal  
12. Systemic lupus erythematosus or ANA > 1:80  
13. History of inflammatory bowel disease, e.g. ul cerative colitis or Crohns disease  
14. Cyclophosphamide in past 90 days, Rituximab in the past 180 days  
15. Pregnancy or nursing  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   13 16. Blood white blood cell count <4,500/mm3; Hg <9 g/dL; Platelet count <150,000/mm3 at 
enrollment. Use of an erythropoiesis stimulating ag ent will not be an exclusion criterion.  
17. Concurrent use of interleukin -1 antagonist (Anakinra), other TNF blocking agent, methotrexate 
or abatacept  
18. Diabetic nephropathy  
 
5.3 STRATEGIES FOR R ECRUITMENT AND RETEN TION  
Patients will be recruited from the active population of patients with FSGS or TR -MCD w at participating 
sites. TR -MCD is defined as persistent proteinuria despite treatment. Following informed consent and 
when appropriate, assent, a screening visit will b e conducted. Patients with elevated TIMP1/Cr and 
MCP1/Cr levels and meeting all other eligibility criteria will be scheduled to receive adalimumab every 
two weeks for 8 weeks (5 total doses). It is anticipated that only 25% of screened patients will be eli gible 
for study participation based on TIMP1/Cr and MCP1/Cr levels. Eight eligible patients will begin study 
intervention with a goal to have a minimum of 6 patients fully completing the intervention phase and 
therefore contributing to the final analysis o f the primary endpoint after 5 doses of adalimumab over an 
8 week period.  
Patients will be compensated for study participation to offset costs related to travel to study visits and 
incidentals.  
 
5.4 PARTICIPANT WITH DRAWAL OR TERMINATIO N 
 
5.4.1  REASONS FO R WITHDRAWAL OR TERMINATION  
Patients participating in this study may withdraw or be terminated for the following anticipated 
reasons.  
● Ongoing participation in this research study is voluntary and patients may leave at any time 
without an identified cause or the need for explanation.  
● Patients experiencing any clinical adverse event (AE), laboratory abnormality, or other 
medical condition  or situation such that continued participation in the study would not be in 
the best interest of the participant (as determined by the patient and/or study physician).  
● Pregnancy and/or breast feeding  
● Absolute contraindications to continued therapy with Hu mira.  
 
5.4.2  HANDLING OF PARTICIPANT WITHDRAWALS OR TERMIN ATION  
Should a participant prematurely withdraw or be withdrawn from the study for any reason, he/she will 
be asked to return for key outcome determinations at study week 10 and final safety assessment at 
study week 14.  At the week 10 visit any medication prescribed by their treating physician since leaving 
the study will be recorded, in addition to other required assessments. The participant’s reason for 
withdrawal and their status at the ti me of withdrawal will be recorded.  Should the participant die, the 
cause of death will be determined and recorded, if possible. This additional data will be utilized in the 
statistical analysis of the primary and secondary study outcomes as defined by the  statistical plan.  
 
5.5 PREMATURE TERMIN ATION OR SUSPENSION OF STUDY  
 
The investigators and/or other regulatory bodies reserve the right to terminate the study at any time. If 
this becomes necessary, appropriate procedures for continuing long -term follow -up and assuring the 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   14 adequate treatment and safety of the participating subjects will be arranged after review and approval 
by the Institutional Review Boards.  
 
The DSMB will also provide external oversight concerning the safety and scientific integrity of t he study 
for the duration of the clinical trial.  The DSMB will review the progress of the study toward meeting 
enrollment goals, adverse and serious adverse event profiles, at regular intervals to occur at least twice 
annually.  The DSMB may recommend at any time that the study should be terminated due to drug 
toxicity, patient safety, poor compliance and/or futility considerations. In such cases, their 
recommendations will be reviewed and discussed with the Executive Committee, which will make a final 
determination.   
 
6 STUDY AGENT  
 
6.1 STUDY AGENT(S) A ND CONTROL DESCRIPTI ON 
 
6.1.1  ACQUISITION  
Each site will be responsible for acquiring and distributing Humira to the study participants in 
accordance with all local institutional policies governing the prescription of drugs for research 
purposes.  
 
6.1.2  FORMULATION, A PPEARANCE, PACKAGING , AND LAB ELING  
Humira is supplied as a sterile, preservative -free solution of adalimumab for subcutaneous 
administration. The drug product is supplied as either a single -use, prefilled pen (Humira Pen), as a 
single -use, 1 mL prefilled glass syringe, or as a single -use institutional use vial. Enclosed within the 
pen is a single -use, 1 mL prefilled glass syringe. The solution of Humira is clear and colorless, with a 
pH of about 5.2.  
 
Formulation and Strength: Any of the commercially available Humira formulations may be used in 
this study:  
●  Each 40 mg/0.4 mL prefilled syringe or prefilled pen delivers 0.4 mL (40 mg) of drug 
product.  
● Each 40 mg/0.8 mL prefilled syringe or prefilled pen  delivers 0.8 mL (40 mg) of drug product.  
● Each 20 mg/0.2 mL prefilled syringe delivers 0.2 mL (20 mg) of drug product.  
● Each 20 mg/0.4 mL prefilled syringe delivers 0.4 mL (20 mg) of drug product.  
 
Labeling On -site: At the Clinical Site Research Pharmacy, p atient specific labeling will be applied to 
Humira as this study drug will be provided in an open -label format to study participants. In addition 
to patient specific labeling information, the drug name, concentration, and date of preparation will 
be on the  label prior to distribution. In accordance with §312.6 the drug will also contain a label with 
the statement “Caution: New Drug – Limited by Federal (or United States) law to investigational 
use.”  
 
6.1.3  PRODUCT STORAG E AND STABILITY  
Humira must be refrig erated at 36°F to 46°F (2°C to 8°C). DO NOT FREEZE. Do not use if frozen even if it 
has been thawed. Store in original carton until time of administration to protect from light. If needed, 
for example when traveling, Humira may be stored at room temperatur e up to a maximum of 77°F 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   15 (25°C) for a period of up to 14 days, with protection from light. Humira should be discarded if not used 
within the 14 -day period. Do not use beyond the expiration date on the container. Record the date 
when Humira is first remove d from the refrigerator in the spaces provided on the carton and dose tray.  
Do not store Humira in extreme heat or cold.  
 
6.1.4  DOSING  
Humira will be dosed based on weight at study weeks 0, 2, 4, 6, and 8. This dose has been selected in 
accordance with the recommended dose of Humira for patients 2 years of age and older with 
polyarticular juvenile idiopathic arthritis.  
 
Subject Weight  Humira dose (every other week)  
15kg to <30kg  20mg  
>30kg  40mg  
 
6.1.5  ROUTE OF ADMIN ISTRATION  
Humira will be given subcutaneously at every other week for 8 weeks (5 total doses).  
 
6.1.6  DOSE ADJUSTMEN TS/MODIFICATIONS/DEL AYS  
If there is evidence of toxicity in abnormal laboratory tests or clinical adverse events that, in the 
judgment of the Investigator, could place the subject at increased risk, study drug administration should 
be interrupted and the investigator should notif y the trial principal investigator at University of 
Michigan. Subjects may be considered eligible to receive further study medication treatment only after 
discussion with the study principal investigator at the University of Michigan.  
 
6.1.7  DURATION OF T HERAPY  
The total duration of therapy will be 8 weeks with a single dose study drug given subcutaneously at 
study weeks 0, 2, 4, 6, and 8.  
 
6.2 STUDY AGENT ACCO UNTABILITY PROCEDURE S 
 
6.2.1  RESPONSIBILITI ES OF THE CLINICAL S ITE PHARMACY  
The dispensing pharma cy at each site will maintain an independent drug accountability log for all 
Humira that is dispensed for this study. The log must include at a minimum: the date dispensed, drug 
expiration date, lot number or other identifying number, and study participant  receiving the drug.  
 
6.2.2  THE SITE INVES TIGATOR RESPONSIBILI TY 
The site team will maintain a drug accountability log for each study patient to document subject 
number, visit number, date medication dispensed, and date medication returned. Any unused 
med ication should be returned to the study site, documented, and disposed of in accordance with local 
policy.  
 
7 STUDY PROCEDURES A ND SCHEDULE  
 
7.1 STUDY PROCEDURES /EVALUATIONS  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   16 Biopsy report: The biopsy report from the qualifying kidney biopsy  will have pers onal identifiers 
redacted, labeled with the study identification number and then submitted into the study database for 
review and confirmation of eligible pathology of FSGS or MCD.  
Archived Kidney Biopsy Tissue: 4 unstained slides from archived paraffin block kidney tissue will be 
submitted for gene expression profiling when available. Patients who have submitted tissue from a 
kidney biopsy as part of NEPTUNE study participation will not be required to have additional tissue 
submitted as part of this stud y. 
Health Related Quality of Life (HRQOL) : The FSGS -MCD Patient Reported Outcome (PRO) assessment 
will be assessed in accordance with the schedule of events table (7.2.5). The FSGS -MCD PRO assessment 
should be completed by the participant at each in -person  study visit.  
Adverse events: Adverse event assessments will be done at each study visit as detailed in Section 9.  
Complete medical history:  The complete medical history will include a review of pertinent medical 
records covering details related to the p atient’s history of FSGS or TR -MCD provided by the patient 
and/or their referring physician(s).  
Physical examination : A physical exam will include a review of systems and current physical findings  
Interval medical history : A review of medications, interval  symptoms, and any changes to the patient’s 
medical history will be reviewed and documented.   
Vital signs:  Vital signs will include: blood pressure, temperature (oC), height (cm), and weight (kg) will be 
measured.   
Pregnancy Testing : For study participants of child -bearing potential, a urine pregnancy test will be 
performed at screening and each study visit prior to adalimumab administration.  
Clinical Laboratories:  A comprehensive set of laboratory results will be performed on blood  and urine 
samples to evaluate any toxicity or adverse events associated with FSGS or TR -MCD or its treatment 
with the study drug.  
● Comprehensive metabolic panel (Comp) : including serum electrolytes, BUN, creatinine, glucose, 
albumin, ALT, AST, alkaline ph osphatase, total bilirubin, cholesterol, total protein  
● Complete blood count with differential (CBCD) : including WBC, hemoglobin, hematocrit, 
platelet count, and differential cell count.  
● Urine protein/creatinine ratio: 24-hour urine collection preferred, b ut first morning urine or 
spot urine is acceptable   
 
Assessment of Infections:   
● Hepatitis B:  HBsAg, HBcAb IgG testing will be conducted at screening for all potentially eligible 
participants unless hepatitis screening has been conducted clinically within the past 45 days 
with documentation of results.  
● Hepatitis C:   HCAb screen will be conducted at screening for all potentially eligible participants 
unless hepatitis screening has been conducted clinically within the past 45 days with 
documentation of results.  
● HIV -1/HIV -2 antibody differentiation immunoassay will be conducted at screening for all  
potentially eligible participants unless HIV screening has been conducted clinically within the 
past 45 days with documentation of results.  
● Tuberculosis: Quantiferon for tuberculosis should be measured unless tuberculosis screening 
has been conducted cli nically within the past 45 days with documentation of results.  
 
Serology:  
● Antinuclear cytoplasmic autoantibody (ANA):  should be measured at screening unless 
conducted clinically within the past 45 days with documentation of results.  
 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   17 Urine collection for target engagement biomarkers: A spot urine sample will be collected at each in 
person study visit before the administration of the study drug.  
Optional Biological Specimen Repository : 10ml of Blood (serum, plasma, RNA and DNA (8.5 ml at the 
screening visit  only)) and urine samples will be collected at each study visit for storage at the University 
of Michigan Biorepository. The specimens will be made available for approved investigations for future 
kidney disease related research.   
Study drug reconciliatio n:  Document subject number, visit number, date medication dispensed, and lot 
number at each visit in accordance with section 6.2.  
Study drug administration:  At week 0 the study team will administer Humira to the subject, and 
monitor the subject for 15 minutes post injection, recording blood pressure and heart rate at 15 minutes 
post injection. Subject/guardian will be taught how to administer Humira to themse lves or their child. At 
week 2, the subject/guardian should administer Humira while study staff observes to ensure proper 
technique. An ice pack may be applied to the injection site to alleviate pain associated with the injection 
as needed.  
 
7.2 STUDY SCHEDULE  
The complete schedule for study visits is detailed below and summarized in the Study Flow Diagram 
(Figure 1) and Table of Study Visits (see below Schedule of Events, Section 7.2.5)  
 
7.2.1  SCREENING VISI T 
The screening visit will take place prefera bly within 2 weeks, but no more than 6 weeks prior to the 
baseline visit (Week 0)  
At the screening visit:  
a. Patient/Parent provides written informed consent and HIPAA authorization prior to any 
evaluation or testing. Minor participants should provide assent in accordance with IRB 
guidelines  
b. A review of existing medical records and tests, provided by the patient or referring 
physician, will be performed to document the history of FSGS or TR -MCD and general 
medical history.  
c. Vital signs including height, weight,  temperature and blood pressure are obtained.  
d. The patient undergoes a physical examination.  
e. The patient has blood and spot urine collected for monitoring labs, including urine 
pregnancy test (if applicable).  
f. A spot urine sample is obtained for measurement of target engagement biomarkers  
g. If the patient consents, biorepository samples should be obtained  
h. Archived kidney biopsy tissue is requested to be sent [when available and if not already 
submitted to the NEPTUNE study] to the laboratory at the University o f Michigan for 
gene expression profiling for mechanisms of disease  
i. Archived kidney biopsy report is anonymized and uploaded into the study electronic 
data capture system for central review  
 
At Screening, a preliminary evaluation is performed and once scre ening is complete, if all inclusion and 
no exclusion criteria are met, the patient is deemed eligible and will be asked to return for the baseline 
visit for study drug initiation.  Subjects who have not met study enrollment criteria will be considered a 
screen failure and their study participation will end.  
 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   18 Repeat Screening. If the patient is found to be ineligible, a repeat screening visit may be performed at 
the local clinician investigator’s discretion.  
 
Once eligibility is confirmed, the patient shoul d be instructed to bring a 24 -hour urine specimen to the 
baseline visit.  
 
7.2.2  BASELINE/WEEK 0 
The Baseline visit/Week 0 will occur within 6 weeks of the screening evaluation.  The following 
procedures will take place at the baseline visit:  
a) Interval medical history  
b) Review of concomitant medications  
c) Physical examination  
d) Assessment of adverse events  
e) Vital signs will be obtained including weight, blood pressure, and temperature  
f) Subject to complete HRQOL assessment  
g) 24-hour urine or first morning urine will be collected from the patient, along with blood 
samples for clinical laboratories, including urine pregnancy (if applicable)  
h) Spot urine collection for biomarkers (TIMP1/Cr and MCP1/Cr).   
i) Blood collection for the Biological Specimen Repository  
j) Humira will be injected subcutaneously, monitor subject for 15 minutes post injection  
k) Record heat rate and blood pressure 15 minutes post injection  
l) Teaching on how to administer subcutaneous injections (to self or minor child)  
m) Remind subject to bring a 24 -hour ur ine sample (or first morning urine if 24 hour sample is not 
feasible) to the next study visit  
 
7.2.3  FOLLOW -UP  
Follow -up Visits (Weeks 2 and 8)  
The following procedures will take place at each of the follow up visits  
a) Interval medical history  
b) Review of concomitant medications  
c) Physical examination  
d) Assessment of adverse events  
e) Vital signs obtained including weight, blood pressure, and temperature  
f) Subject to complete the HRQOL assessment  
g) 24-hour urine or first morning urine will be collected from the patient, along with blood 
samples for clinical laboratories, including urine pregnancy (if applicable)  
h) Spot urine collection for biomarkers (TIMP1/Cr and MCP1/Cr)  
i) Blood collection for the Biological Specimen Repository  
j) Subject to administer Humira to thems elves (or child) under the guidance of study staff  
k) Remind subject to bring a 24 -hour urine sample (or first morning urine if 24 hour sample is not 
feasible) to the next study visit  
 
Endpoint Visit (Weeks 10)  
The week 10 follow -up visit includes a combinati on of toxicity monitoring and outcome 
assessments.  
a) Interval medical history  
b) Review of concomitant medications  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   19 c) Physical examination    
d) Assessment of adverse events  
e) Vital signs obtained including weight, blood pressure, and temperature  
f) Subject to complete the HRQOL assessment  
g) 24-hour urine or first morning urine will be collected from the patient, a fresh spot urine will be 
collected during the visit along with blood samples for clinical laboratories, including urine 
pregnancy (if appli cable)  
h) Spot urine collection for biomarkers (TIMP1/Cr and MCP1/Cr)  
i) Blood biorepository sample collection  
 
Safety Visit (Week 14)  Phone visit or optional in -person study visit may be preformed  
a) Interval medical history  
b) Review of concomitant medications  
c) Assessment of adverse events   
d) If the optional in -person visit is scheduled:  
a. Physical examination  
b. Vital signs obtained including weight, blood pressure, and temperature  
c. Blood sample for clinical laboratories  
d. 24-hour urine or first morning urine will be collected from the patient, a fresh 
spot urine will be collected during the visit along with blood samples for clinical 
laboratories, including urine pregnancy (if applicable)  
      
7.2.4  EARLY TERMINAT ION VISIT  
Should a  participant prematurely withdraw or be withdrawn from the study for any reason he/she will 
be asked to return for the key outcome determinations (week 10 assessments), as detailed above. In 
addition, at that time, any medication prescribed by their treati ng physician since leaving the study will 
be recorded. The participant will also be asked to participate in additional safety monitoring visits (week 
14) as described in 7.2.3 if at least one dose of the study medication was administered. Should the 
partic ipant die, the cause of death will be determined and recorded, if possible. This additional data will 
be utilized in the statistical analysis of the primary and secondary study outcomes and any missing data 
handled by appropriate statistical methods.  
 
7.2. 5 SCHEDULE OF EVENTS  TABLE  
 
 Screening  Week 0  Week 2  Week 8  Week 10  Week 14  
Visit window  +/-2 
DAYS  +/-2 
DAYS  +/-2 
DAYS  +/-2 
DAYS  +/-2 
DAYS  +/-4 
DAYS  
Consent  X      
Medical History  X X X X X X 
Archived Kidney Biopsy Report 
Submission  X      
Archived Kidney Tissue 
sections submitted, if 
available*        
Concomitant Medications  X X X X X X 
Physical Exam  X X X X X X** 
Adverse Events Assessment   X X X X X 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   20 Vital Signs  X X X X X X** 
HRQOL assessment   X X X X  
Comprehensive Metabolic 
Panel  X X X X X X** 
CBC with Platelets and 
Differential  X X X X X X** 
Urine Protein:Creatinine [24 
hour sample preferred]  X X X X X X** 
Assessment of Infections  X      
MCP1/TIMP1 (spot urine)  X X X X X  
Pregnancy Test  X X X X   
Biorepository specimen  X*      X X X X  
Adalimumab dosing   X X X   
* Do not submit if most recent biopsy specimen has already been submitted to NEPTUNE study; *DNA 
collected at screening only  
** Optional procedures required if study visit is conducted in -person  
 
7.3 JUSTIFICATION FOR SE NSITIVE PROCEDURES  
HIV, hepatitis B and hepatitis C testing is a part of the screening procedures as therapy with adalimumab 
is contraindicated for persons with active infections. Should HIV, hepatitis B, hepatitis C or 
tuberculosis/qua ntiferon testing be positive, the patient will be referred for clinical care through local 
treatment experts according to local standards of care and excluded from the study.  
7.4 CONCOMITANT MEDI CATIONS, TREATMENTS,  AND PROCEDURES  
All concomitant prescri ption, over -the-counter and non -prescription medications taken during study 
participation will be recorded on the case report forms (CRFs) and checked for compatibility with the 
study drugs as defined in Section 7.5.  
 
7.5 PROHIBITED MEDIC ATIONS, TREATMENT S, AND PROCEDURES  
Patients should not receive live vaccines while taking Humira and for 3 months following the final 
adalimumab dose. Participants should not take anakinra, abatacept, or rituximab in combination with 
Humira.  
 
7.6 PARTICIPANT ACCE SS TO ST UDY AGENT AT STUDY C LOSURE  
Humira is approved by the FDA for use in other health conditions. Consequently, it may be prescribed 
off label by the patient’s local nephrologist per local clinical decision making.  
 
8 ASSESSMENT OF SAFE TY 
All adverse events, whether serious or non -serious, related or not related, following exposure to 
adalimumab are to be documented by the investigator and recorded in the CRF and in the subject’s 
source records. Investigators must record in the CRF their opinion concerning the  relationship of the 
adverse event to the study drug.  
  
All reported serious and non -serious adverse events should be followed up in accordance with clinical 
practice.  
 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   21 8.1 SPECIFICATION OF  SAFETY PARAMETERS  
 
8.1.1  DEFINITION OF ADVERSE EVENTS (AE)  
An adve rse event is any untoward medical occurrence in a clinical study subject administered a 
medicinal (investigational or non -investigational) product. An adverse event does not necessarily have a 
causal relationship with the treatment. An adverse event can th erefore be any unfavorable or 
unintended sign (including an abnormal finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational or non - investigational) product, whether or not related to that 
medicinal (investigationa l or non -investigational) product. (Definition per International Conference on 
Harmonisation [ICH])  
 
This includes any occurrence that is new in onset or aggravated in severity or frequency from the 
baseline condition, or abnormal results of diagnostic pro cedures, including laboratory test 
abnormalities.  
 
Adverse events may include:  
• Symptoms described by the patient  
• Clinically significant changes in the patient’s physical exam or other signs observed by the investigator 
or medical staff  
• Test abnormali ties (laboratory tests, ECG, X -rays, etc.) that reflect a change from baseline and/or that 
may result in changes in administration of investigational product or in an alteration in medical care 
(diagnostic or therapeutic)  
• Conditions present at baseline t hat have either worsened or recurred following resolution  
 
The patient will be evaluated for new AEs and the status of existing AEs at each study visit, or at any 
time contact is made with the patient outside of a scheduled visit. The Investigator may eli cit symptoms 
using an open -ended question, followed by appropriate questions that clarify the patient’s description 
of AEs.  
 
8.1.2  DEFINITION OF SERIOUS ADVERSE EVEN TS (SAE)  
An SAE is an AE that results in any of the following:  
• Death: the patient died as  a result of the event. The cause of death of a subject in a study within 30 
days of the last dose of study drug, whether or not the event is expected or associated with the study 
drug, is considered a serious adverse event.  
• Is life -threatening: An AE th at places the patient, in the view of the Investigator or sponsor, at 
immediate risk of death from the AE as it occurred, i.e., does not include an AE that had it occurred in a 
more severe form, might have caused death.  
• Requires inpatient hospitalization  or prolongation of existing hospitalization:  
o Note: Planned or elective hospital admissions for treatment/procedures for a condition/disease 
that existed prior to signing the informed consent should be recorded in the patient’s screening 
documents and will  not be captured as SAEs. If, however, the admission or procedure occurs 
other than as planned due to a worsening of the condition, then the event should be recorded 
as a SAE. Hospitalizations not intended to treat an acute illness or adverse event (e.g., social 
reasons such as pending placement in long -term care facility) should not be recorded as an SAE.  
• Persistent or significant disability/incapacity: An AE that results in a substantial disruption of a person’s 
ability to conduct normal life functions.  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   22 • Pregnancy, or Congenital anomaly/birth defect: A pregnancy in an individual receiving the 
investigational product or congenital anomaly/birth defect that occurs in the offspring of a patient 
exposed to the investigational product.  
• Other Medically Impo rtant Events: An AE that may not result in death, be life threatening, or require 
hospitalization may be considered a serious adverse event when, based upon appropriate medical 
judgment, the event may jeopardize the patient and may require medical or surgi cal intervention to 
prevent one of the outcomes listed in this definition  
Medical and scientific judgment should be exercised in deciding whether expedited reporting is also 
appropriate in other situations, such as important medical events that may not be immediately life 
threatening or result in death or hospitalization but may jeopardize the subject or may require 
intervention to prevent one of the other outcomes listed in the definition above. These should usually 
be considered serious.  
Any situation tha t meets the criteria of a serious adverse event should be recorded on a Serious 
Adverse Event Report Form and be reported within 24 hours of becoming aware of the event to the 
IRB (per local policies), and the study Principal Investigator.  
All serious adve rse events that have not resolved by the end of the study, or that have not resolved 
upon discontinuation of the subject's participation in the study, must be followed until any of the 
following occurs:  
● The event resolves  
● The event stabilizes  
● The event ret urns to baseline, if a baseline value/status is available  
● The event can be attributed to agents other than the study drug or to factors unrelated to study 
conduct  
● It becomes unlikely that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration of 
due diligence with follow -up efforts)  
 
8.1.3  PREGNANCY  
Females of child bearing potential must use birth control for 30 days prior to the first dose of 
adalimumab through 30 days after the last dose of adalimumab.  
All initial reports of pregnancy must be reported within 24 hours of becoming aware of the event  using 
the Serious Adverse Event Form. Abnormal pregnancy outcomes (e.g. spontaneous abortion, fetal death, 
stillbirth, congenital anomaly, ectopic pregnancy) are considered serious adverse events and must be 
reported using the Serious Adverse Event Form.  
Follow -up information regarding the outcome of the pregnancy and any postnatal sequelae in the infant 
will be required.  
 
8.2 CLASSIFICATION O F AN ADVERSE EVENT  
 
8.2.1  SEVERITY OF EV ENT  
Severity indicates the intensity of the event and should not be confused with seriousness (see sections 
8.1.1 and 8.1.2 for assessing seriousness).  
Severity Grading: The Investigator will assess the severity of all AEs/SAEs as Mild, Moderate, or Severe, 
based on the following definitions.  
Definitions:  
• Mild – Awarenes s of the event but easily tolerated  
• Moderate – Discomfort enough to cause some interference with usual activity  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   23 • Severe – Inability to carry out usual activity  
 
8.2.2  RELATIONSHIP T O STUDY AGENT  
Assessment of the relationship between the AE and exposure  to the investigational product is important 
for regulatory reporting and assists in the overall analysis of the safety information. For each AE/SAE the 
Investigator must determine whether, based on available evidence, there is a reasonable possibility tha t 
the study drug caused the event. Causal relationship to study drug administration is based on the 
following definitions:  
• None: No relationship between the event and the administration of study drug. The event is related to 
other etiologies, such as con comitant medications or the patient’s clinical state.  
• Unlikely: The current state of knowledge indicates that a relationship to study drug is unlikely or the 
temporal relationship is such that study drug would not have had any reasonable association with  the 
observed event.  
• Possible: A reaction that follows a plausible temporal sequence from administration of the study drug 
and follows a known response pattern to the suspected study drug. The reaction might have been 
produced by the patient’s clinical s tate or other modes of therapy administered to the patient.  
• Related: The administration of study drug and AE were reasonably related in time and the AE was 
more likely explained by exposure to the study drug than by other causes. There is clear evidence to 
suggest a causal relationship, and other possible contributing factors can be ruled out.  
A causality assessment must be provided for each AE/SAE recorded, even if there is only limited 
information at the time. Upon receipt of follow -up information, the Investigator may change his/her 
assessment of causality and amend the AE/SAE report accordingly.  
For the purpose of safety analyses, all AEs that are classified as possible will be considered treatment -
related events.  
8.2.3  EXPECTEDNESS  
An adverse event is considered unexpected if the nature or severity is not consistent with the applicable 
product reference safety information. See Appendix A.  
 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLO W-UP 
Participants should be monitored for adverse events throughout the study with the final assessment 
occurring at week 14.  
 
8.4 REPORTING PROCED URES  
 
8.4.1  ADVERSE EVENT REPORTING  
All AEs will be captured from the time informed consent is signed through th e week 14 visit. AEs should 
be recorded using appropriate medical terminology. When recording, it is preferable to provide a 
diagnosis. Sufficient information should be sought to assist the Investigator both in determining the 
diagnosis and in making a cau sality assessment.  
Reporting should not be delayed pending receipt of all required information. If information is 
unavailable at the time of the initial report, the Investigator is expected to follow -up until the required 
information has been obtained  
 
8.4.2 SERIOUS ADVERSE EVENT REPORTING  
All SAEs including pregnancy must be reported to the study Coordinating Center University of Michigan 
through the Electronic Data Capture System, notification of the study Principal Investigator, and the 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   24 study IRB of re cord within 24 hours of the Investigator’s first knowledge of the event, regardless of 
causal relationship.  SAEs will be reported to the FDA in accordance with §312.32.  
• A completed Clinical Study SAE Report Form containing a detailed written descriptio n of the event 
along with available supporting documents (e.g., discharge summary, autopsy report, diagnostic test 
results, etc.) should be submitted to the data coordinating center  
• Additional information that is not available at the time the initial SAE  Report Form was completed, 
must be promptly reviewed and provided to The University of Michigan within 48 hours of receipt. Full 
supporting documentation should be solicited by the investigative site even if the SAE occurred at 
another institution. Such d ocumentation may include copies of relevant patient/hospital records, 
discharge summaries, laboratory/test results or autopsy reports.  
• If, at any time after the patient has completed participation in the study, the Investigator or study staff 
becomes awa re of an SAE that they suspect is related to the investigational product, then the event and 
any known details must be reported promptly to the University of Michigan based Principal Investigator 
and coordinating center.  
 
8.5 STUDY HALTING RU LES  
As this s tudy intends to treat a maximum of 8 patients in this study protocol, no halting rules have been 
defined a priori. Routine study safety monitoring will be performed by the study Data Safety and 
Monitoring Board.  
 
8.6 SAFETY OVERSIGHT  
Safety oversight will  be provided by the study DSMB. Due to the small sample size, the DSMB chair will 
be notified of Serious Adverse Events until completion of the trial. The DSMB will review the trial 
protocol prior to enrollment initiation and with any substantial protocol amendments. Safety outcomes 
will be presented at each DSMB meeting. These include number of and proportion of subjects with SAEs 
(including segregation of those involving deaths), treatment emergent AEs, and discontinuation of study 
medication due to AEs. These presentations will be descriptive, with no formal inferential methods used.  
Serious Adverse Events and related or possibly related unexpected adverse events will be reported to 
the study IRB of record according to their reporting requirements. Parti cipating trial sites will be notified 
of these events with an indication if a change in consent form is recommended.  
 
9 CLINICAL MONITORIN G 
Monitoring is the act of overseeing the progress of the study and of ensuring that it is conducted, 
recorded and reported in accordance with the protocol, standard operating procedures, good clinical 
practice standards, and the applicable regulatory requirements. Given the sample size, monitoring for 
this study will be done remotely.  
Data entered into the case report  forms will be reviewed for completion, integrity, and quality. Data 
reports will be shared with the sites and the steering committee. Data to be reviewed includes: 
enrollment, visit completion, data completeness, outstanding queries, biosample collection and 
shipping.  
The study monitoring staff may conduct site management calls to ensure data compliance and data query 
resolution. Other topics may include:  
• Protocol adherence  
• Recruitment and retention strategies  
• Regulatory document requirements  
• Compl eteness of visits, forms, data, and samples  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   25 • Responses to data queries  
• Electronic Case Report Forms (eCRFs) and source documents  
• Study -specific training  
 
10 STATISTICAL CONSI DERATIONS  
 
10.1  STATISTICAL AND  ANALYTICAL PLANS  
This is a pilot, proof of concept investigation to test the proposed biomarkers as an indicator of target 
engagement.  As such, no formal sample size calculations are performed and analyses are primarily 
descriptive in nature.  Our approach will be to assess the biomarker change ov er time with TNF 
inhibition therapy within each patient and as a group. As the Elisa testing for this indication is new, the 
protocol will use an exploratory approach to assess individual and panel biomarker change and 
correlation with clinical indicators of disease, including proteinuria, eGFR, and serum albumin.  
A statistical analysis plan (SAP) will be written for the study that contains detailed descriptions of the 
analyses to be performed.  The SAP will be finalized prior to database lock.  
 
10.2  ANALY SIS DATASETS  
All eligible participants who receive at least one dose of adalimumab (as -treated population) will be 
analyzed for primary, secondary and exploratory endpoints.   
 
10.3  DESCRIPTION OF STATISTICAL METHODS  
 
10.3.1  GENERAL APPRO ACH  
Analyses are primarily descriptive in nature in this pilot study.   Continuous variables will be summarized 
using descriptive statistics including n, mean, median, standard deviation, interquartile range (i.e., 1st 
and 3rd quartiles), and range (i.e., minimum and maxim um). Qualitative variables will be summarized 
using counts and percentages.  Unless otherwise specified, statistical analyses will be performed using 
SAS Version 9 or higher. Where appropriate, statistical tests will be conducted at the 0.05 significance 
level using two‐tailed tests and p‐values will be reported.  
 
10.3.2  ANALYSIS OF T HE PRIMARY EFFICACY ENDPOINT(S)  
The change in urine MCP1/Cr and TIMP1/Cr levels from baseline to study week 10, i.e. 2 weeks after the 
final dose of adalimumab, are the primary  endpoints.  We will provide tabular and graphical summaries 
of the changes from baseline to week 10 in MCP1/Cr and in TIMP1/Cr, including summaries at baseline 
and week 10. The changes from baseline to week 10 in urine MCP1/Cr and TIMP1/Cr levels will be tested 
using the paired t -test or Wilcoxon signed -rank test (if distributional assumptions are not met).  
 
10.3.3  ANALYSIS OF T HE SECONDARY ENDPOIN T(S)  
Discrete outcomes (e.g., AEs, SAEs, proportion of participants achieving a nadir UPC <1.5 g/g and <40% 
from baseline) will be summarized descriptively.  Continuous outcomes (e.g., changes in eGFR, change in 
proteinuria) will be summarized descriptively, including baseline, follow -up and changes from baseline.     
 
10.3.4  SAFETY ANALYS ES 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   26 Safety data, including  frequency of events and proportion of participants experiencing events (e.g., 
treatment -emergent AEs and SAEs by body system, severity and relatedness to adalimumab), clinical 
laboratory tests, vital signs, and physical examinations, will be summarized de scriptively.   
 
10.3.5  ADHERENCE AND  RETENTION ANALYSES  
Subject disposition, including descriptive statistics on -treatment and on -study follow -up, will be 
reported.  Listings of subject disposition, including reasons for early termination, will be reported .   
Other disposition and study conduct information, including major protocol violations, will be 
summarized.  
 
Compliance with study medication will be assessed and summarized, including the proportion of 
participants who adhered to study treatment, the me dian duration of adherence to study treatment and 
the proportion of participants who permanently discontinued study medication.   
 
10.3.6  BASELINE DES CRIPTIVE STATISTICS  
Demographic data and baseline characteristics will be summarized . 
 
10.3.7  TABULATION OF INDIVIDUAL RESPON SE DATA  
Listings of SAEs, AEs and AEs resulting in treatment discontinuation will be provided.  
 
10.3.8  EXPLORATORY A NALYSES  
Spearman correlations and scatterplots will be provided to assess the correlation of intra -renal gene 
expression of TNF and urine biomarker levels at baseline.  Continuous outcomes (e.g., changes in QOL 
outcomes, EGF biomarker levels) will be summarized de scriptively, including baseline, follow -up and 
changes from baseline.   
 
10.4  SAMPLE SIZE  
No formal sample size calculations were performed (either for estimation or hypothesis testing) because 
this study is a pilot investigation of urine biomarkers for ta rget engagement of TNF inhibition. Rather, 
we assessed the magnitude of effects that can be detected in urine biomarkers using a paired t -test.  
With 6 patients, 80% power, and a two -sided type I error of 10%, we can detect an effect size (change 
from base line to week 10 / SD) of 1.2 of changes in uTIMP1/Cr and of changes in uMCP1/Cr, with no 
adjustments for multiplicity (EAST 6.2).  
 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE  DATA/DOCUMENTS  
Every participating clinical site will maintain appropriate medical and research records for this trial, in 
compliance with GCP, regulatory and institutional requirements for the protection of confidentiality of 
participants. Participating clinical sites w ill also obtain institutional authorization for external monitoring 
by the Data Coordinating Center to examine (and when permitted by applicable law, to copy) clinical 
records for the purposes of quality assurance reviews, audits, and evaluation of the stu dy safety, 
progress, and data validity.  
 
Source data are defined as all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Examples of the se 
original documents and data records include, but are not limited to, hospital records, clinical and office 
charts, laboratory notes, memoranda, participant’s memory aids or evaluation checklists, pharmacy 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   27 dispensing records, recorded audio tapes, record ed data from automated instruments, copies or 
transcriptions certified after verification as being accurate and complete, microfiches, photographic 
negatives, microfilm x -rays, and participant files and records kept at the pharmacy, at the laboratories, 
and medico -technical departments involved in the clinical trial. It is acceptable to use CRFs as source 
documents when the data is collected and recorded there as the primary source of information, but 
CRFs will not constitute the only form of source documen t information for this trial.  
 
12 ETHICS/PROTECTION  OF HUMAN SUBJECTS  
 
12.1  ETHICAL STANDAR D  
The study will be monitored by clinical study monitors to assess adherence to good clinical practice and 
to this clinical study protocol.  
 
The study may be audit ed by the regulatory authorities, the IRB, and/or the US Food and Drug 
Administration. Direct access to these documents must be guaranteed by the Investigator, who must 
provide support at all times for these activities.  
 
12.2  INSTITUTIONAL R EVIEW BOARD  
This protocol, investigator’s brochure, informed consent documents, and any other patient facing 
materials must be reviewed and approved in accordance with the IRB of Record’s policies prior to any 
study procedures taking place.  
 
12.3  INFORMED CONSEN T PROCES S  
Each site is responsible for ensuring that informed consent and assent, when applicable, is obtained 
from each patient using a current consent form according to the guidelines of its local IRB and in 
accordance with the Common Rule (45 CFR Part 46 subpa rt A, Protection of Human Subjects). The 
informed consent (ICF) and assent forms must be signed and dated by the patient or the legal guardian 
if applicable prior to initiation of any study -related activity.  During the consent process, the study team 
will discuss the implications of participation in this study and that the drug dosing under study has not 
been studied previously. All participant questions should be fully answered before the ICF is signed. The 
signed ICF should be placed in the subject’s res earch file and copies should be provided to the study 
participant as well as placed in the participant’s medical chart according to local regulatory 
requirements.  
 
The ICF as well as any other patient -facing documents, such as the quality of life forms or  recruitment 
materials must be approved in accordance with the site’s local IRB requirements.  
Consenting Non -English Speaking Participants: Obtaining consent from non -English speaking participants 
should be conducted in accordance with IRB guidelines.  
 
12.4  PARTICIPANT AND  DATA CONFIDENTIALIT Y  
Participant identifiers will only be known to the local study team. Any information that leaves the local 
study site should be identified with the participant’s study ID number and no identifying information. 
Data  must be kept in a secure location at the local site. The study database will be on a secure University 
of Michigan server.  
 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   28 12.5  FUTURE USE OF S TORED SPECIMENS  
The Steering Committee, including the study PI, PI from each participating site, and DCC PI, oversee all 
requests (both internal and external to the study) to access stored samples and data for ancillary studies 
directed toward the understanding of nephrotic syndrome, kidney disease, and/or the treatment 
protocol.  
 
Once the steering committee for this clinical trial has completed their responsibilities (study closed, 
analysis complete, results reported) the stewardship of the stored biospecimens for future research will 
be under the NIH sponsored Nephrotic Syndrome Study Network (NEPTUNE) ancillary  studies 
committee.  
 
13 DATA HANDLING AND  RECORD KEEPING  
 
13.1  DATA COLLECTION  AND MANAGEMENT RESP ONSIBILITIES  
Data will be collected on study Case Report Forms and entered into the study electronic data base.  
Entered data will be assessed for complete ness, accuracy, and timeliness. Queries will be distributed 
from the coordinating center to the study site personnel to maximize the data quality and accuracy.  
 
13.2  STUDY RECORDS R ETENTION  
Study records will be maintained for 2 years after completion of  the trial.  
 
13.3  PROTOCOL DEVIAT IONS  
Protocol deviations will be reported to the study IRB and the study coordinating center. Every effort will 
be made to avoid protocol deviations except in the setting of patient safety.  
 
13.4  PUBLICATION AND  DATA SHARING POLICY  
This trial is expected to be reported as a scientific publication and will follow the publication and data 
sharing policies of the NEPTUNE study and the Kidney Research Network (KRN). (NEPTUNE -Study.org 
and kidneyresearchnetwork.org)  
14 CONF LICT OF INTEREST POL ICY 
Participating investigators and research personnel are responsible to maintain compliance with local and 
national conflict of interest policies.  
 
15  LITERATURE REFER ENCES  
1. KDIGO Board Members. Kidney international supplements. Mar 2012;2(1):3.  
2. Gadegbeku CA, Gipson DS, Holzman LB, et al. Design of the Nephrotic Syndrome Study Network 
(NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney 
international. Apr 2013;83(4):749 -756.  
3. Trachtman H, Vento S, Herreshoff E, et al. Efficacy of galactose and adalimumab in patients with 
resistant focal segmental glomerulosclerosis: report of the font clinical trial group. BMC 
nephrology. 2015;16:111.  
4. Ternant D, Paintaud G, Trachtman H, Gipson DS, Joy  MS. A possible influence of age on 
absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). 
European journal of clinical pharmacology. Feb 2016;72(2):253 -255.  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   29 5. Joy MS, Gipson DS, Powell L, et al. Phase 1 trial of adalimumab  in Focal Segmental 
Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study 
group. American journal of kidney diseases : the official journal of the National Kidney 
Foundation. Jan 2010;55(1):50 -60. 
6. Roberts BV, Susan o I, Gipson DS, Trachtman H, Joy MS. Contribution of renal and non -renal 
clearance on increased total clearance of adalimumab in glomerular disease. Journal of clinical 
pharmacology. Sep 2013;53(9):919 -924.  
7. Joy MS, Gipson DS, Dike M, et al. Phase I tria l of rosiglitazone in FSGS: I. Report of the FONT 
Study Group. Clinical journal of the American Society of Nephrology : CJASN. Jan 2009;4(1):39 -
47. 
 
APPENDIX  
 
A. Humira Product Information  
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   30 
 
 
Precision Medicine Proof of Concept for TNF Inhibition in FSGS and TR -MCD  Version 5.0 
      February 21, 2023  
NIH-FDA Clinical Trial Protocol Template – v0.1 20160205   31  
 